세계의 RWE(Real World Evidence) 솔루션 시장 : 구성요소별, 용도별, 배포 모드별, 수익 모델별, 최종 사용자별, 지역별, 비즈니스 모델별 - 예측(-2029년)

Real World Evidence Solutions Market by Component (Services, Disparate Data Sets), Application, Mode of Deployment, Revenue Model, End Users, & Region, Business Model - Global Forecast to 2029

US $ 4,950 ￦ 6,814,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650 ￦ 9,155,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,220,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 13,767,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 RWE(Real World Evidence) 솔루션 시장 규모는 2024년 20억 달러에서 예측 기간 동안 16.5%의 연평균 복합 성장률(CAGR)(연평균 성장률)로 2029년 45억 달러 규모로 성장할 것으로 예상됩니다.

시장 성장의 원동력은 볼륨 기반 치료에서 가치 기반 치료로의 전환이 가속화되고 고령 인구 증가에 따른 것입니다. RWE(Real World Evidence)는 의약품 개발 과정에서 비용과 시간을 모두 절감할 수 있는 잠재력을 가지고 있습니다. 이러한 이유로 많은 제약 및 의료기기 업체들이 RWE를 채택하고 있으며, 이는 예측 기간 동안 시장 성장의 원동력이 될 것으로 보입니다. 반면, 숙련된 인력의 부족과 RWE의 설계, 실행, 분석 및 보고를 관리할 수 있는 보편적으로 인정된 기준과 원칙이 없습니다는 점은 시장 성장에 큰 걸림돌로 작용하고 있습니다.

조사 범위

조사 범위
조사 대상년도	2022-2029년
기준년도	2023년
예측 기간	2024-2029년
단위	금액(USD)
부문	구성요소, 용도, 도입 형태, 수익 모델, 최종사용자
대상 지역	북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카

구성 요소별로는 서비스 부문이 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다. 서비스 부문에는 고급 분석 서비스와 컨설팅 서비스가 포함됩니다. 이러한 서비스는 의미 있는 정보 패턴을 추출하는 데 중요한 역할을 하며, 임상의가 정보에 입각한 치료 결정을 내릴 수 있도록 돕습니다. 또한 RWE 및 운영 계획 개발을 위한 다기능 워크샵을 실시하여 최종 사용자를 지원합니다.

또한, 용도별로는 의약품 개발 및 승인 부문이 예측 기간 동안 가장 큰 성장세를 보일 것으로 예상됩니다. 또한, 암 분야가 가장 큰 성장세를 보일 것으로 예상됩니다. 항암제 관련 임상시험 증가와 전 세계적으로 암 환자 수가 급증하면서 이 분야의 성장을 견인하고 있습니다. 세계보건기구(WHO)에 따르면, 증거에 기반한 예방 전략을 실행하고 위험 요인을 피함으로써 암의 약 30-50%를 예방할 수 있다고 합니다.

지역별로는 아시아태평양이 예측 기간 동안 가장 높은 CAGR을 보일 것으로 예상됩니다. 이 지역의 성장은 제약사 및 의료기기 회사들이 RWE를 채택하기 위한 정부 이니셔티브의 확대에 기인합니다. 또한, 이 지역의 임상시험은 비용 효율성이 매우 높기 때문에 이 지역에서 수행되는 임상시험의 수가 증가하고 있습니다.

세계 RWE(Real World Evidence) 솔루션 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 기술 및 특허 동향, 규제 환경, 사례 연구, 시장 규모 추이 및 예측, 각종 부문별/지역별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다. 주요 기업 프로파일 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 프리미엄 인사이트

제5장 시장 개요

• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
• 업계 동향
• 리얼월드 데이터 소스
• 생태계 분석
• 밸류체인 분석
• 고객의 비즈니스에 영향을 미치는 동향/파괴적 변화
• Porter의 Five Forces 분석
• 가격 분석
• 기술 분석
• 관세 및 규제 상황
• 특허 분석
• 주요 컨퍼런스 및 이벤트
• 주요 이해관계자와 구입 기준
• 사용예/사례 연구
• 최종사용자 분석
• RWE 솔루션 비즈니스 모델

제6장 세계의 RWE 솔루션 시장 : 컴포넌트별

• 서비스
• 데이터 세트
  • 이종 데이터 세트
  • 통합 데이터 세트

제7장 세계의 RWE 솔루션 시장 : 용도별

• 의약품 개발 및 승인
  • 종양
  • 순환기질환
  • 신경
  • 면역
  • 기타
• 의료기기 개발 및 승인
• PMS(제조 판매 후 조사)
• 시장 접근과 상환/보상 범위 의사결정
• 임상 및 규제에 관한 의사결정

제8장 세계의 RWE 솔루션 시장 : 수익 모델별

• 종량 빌링(밸류 기반 요금 설정)
• 구독

제9장 세계의 RWE 솔루션 시장 : 전개 모드별

• 온프레미스
• 클라우드 기반

제10장 세계의 RWE 솔루션 시장 : 최종사용자별

• 제약 및 의료기기 기업
• 의료 보험자
• 의료 제공업체
• 기타

제11장 세계의 RWE 솔루션 시장 : 지역별

• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제12장 경쟁 구도

• 주요 기업이 채택하는 성공 접근
• 매출 점유율 분석
• 시장 점유율 분석
• 시장 순위 분석
• 브랜드/제품 비교 분석
• RWE 솔루션 벤더 평가와 재무 지표
• 기업 평가 매트릭스 : 주요 기업
• 기업 평가 매트릭스 : 신규 기업/중소기업
• 경쟁 시나리오

제13장 기업 개요

• 주요 기업
  • IQVIA HOLDINGS INC.
  • MERATIVE
  • OPTUM, INC.
  • ICON PLC
  • SYNEOS HEALTH, INC.
  • PAREXEL INTERNATIONAL CORPORATION
  • THERMO FISHER SCIENTIFIC INC.
  • FORTREA INC.
  • ORACLE CORPORATION
  • ELEVANCE HEALTH, INC.
  • SAS INSTITUTE INC.
  • AETION, INC.
  • TRINETX LLC
  • TRINITY
  • PERKINELMER INC.
  • COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION
  • CEGEDIM HEALTH DATA
  • VERANTOS
  • MEDPACE HOLDINGS, INC.
• 기타 기업
  • HEALTHVERITY, INC.
  • DATAVANT
  • SYAPSE, INC.
  • TEMPUS
  • FLATIRON HEALTH
  • QUANTZIG

제14장 부록

LSH

영문 목차

영문목차

The global Real-World Evidence Solutions market is projected to reach USD 4.5 Billion by 2029 from USD 2.0 billion in 2024, at a CAGR of 16.5% from 2024 to 2029. The growth of the market is fuelled by an upsurging shift from volume to value-based care and rise in geriatric population. Real-world evidence (RWE) holds the potential of cutting down both costs and time in the drug development process. This has resulted in a growing adoption of RWE within numerous pharmaceutical and medical device companies, leading to drive the market growth throughout the forecast period. But scarcity of skilled personnel, and absence of universally acknowledged standards or principles governing the design, execution, analysis, and reporting of Real-World Evidence (RWE) poses a significant challenge within this market.

Scope of the Report
Years Considered for the Study	2022-2029
Base Year	2023
Forecast Period	2024-2029
Units Considered	Value (USD) Billion
Segments	Components, Application, Mode of Deployment, Revenue Model and End user
Regions covered	North America, Europe, Asia Pacific, Latin America, and Middle East Africa

"Real-World Evidence Solution, services segment to witness the highest growth during the forecast period."

Based on component, the Real-World Evidence Solution market is segmented into Real-World Evidence Solution services and Real-World Evidence Solution data sets. In 2023, service segment is projected to grow at the highest CAGR during the forecast period. The service segment encompasses advanced analytic services and consulting services. These services play a crucial role in extracting meaningful patterns of information, enabling clinicians to make informed treatment decisions. Additionally, they help end users in conducting multifunctional workshops for the development of Real-World Evidence (RWE) and operational plans. Furthermore, experts in Real-World Evidence (RWE) actively communicate and collaborate with subject matter experts from pharmaceutical and medical devices companies. This collaboration aims to provide services that contribute to the formulation of intelligent strategies, ultimately driving growth the services segment throughout the forecast period.

"Drug and Development and approval segment to register the highest growth in the Real-World Evidence Solution market during the forecast period."

Based on application, the Real-World Evidence Solution market is segmented into drug development and approvals, medical device development and approvals, post market surveillance, market access and reimbursement/coverage decision making, Clinical & regulatory decision making. The drug development and approval segment dominate the market by application. The drug development and approvals market are further bifurcated into oncology, neurology, cardiovascular diseases, immunology, and other therapeutic areas. The oncology segment holds the largest position in drug development and approval segment. This is attributed to the increasing number of clinical trials conducted on cancer drugs, and upsurging number of cancer patients across the globe drives the segmental growth. As per World Health Organization (WHO), the implementation of evidence-based prevention strategies and the avoidance of risk factors have the potential to prevent approximately 30 to 50% of cancers.

"Pharmaceutical and medical device companies' segment to register the highest growth in the Real-World Evidence Solution market during the forecast period."

Based on end user, the RWE solution market is segmented into pharmaceutical and medical devices companies, healthcare payers, healthcare providers, and other end-users which includes CROs, academic institutions, patient advocacy groups, and HTA agencies. In 2023 the pharmaceutical and medical device companies hold the largest share among the end users. This is due to many companies are adapting the RWE solutions to decrease the cost and time for the drug development process, as RWE data helps new drugs and new medical devices to successfully pass through the clinical trials phases.

"APAC is estimated to register the highest CAGR during the forecast period."

In this report, the Real-World Evidence Solution market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The RWE solution market in APAC is projected to register the highest CAGR rate during the forecast period. The growth of this region is due to rise in government initiatives towards the adoption of RWE by the pharmaceutical and medical device companies. Moreover, the clinical trials in this region are very cost-effective thus increasing the number of clinical trials being conducted in this region. For instance, according to the NOVOTECH report published in May 2022, on the Evolution of Clinical Trials in the Asia Pacific Region in comparison to the US and the EU5, a total of over 70,000 new clinical trials were recorded across the APAC region, the US, and the EU5 during the analysis period from 2017 to 2021. Notably, the APAC region emerged as the primary contributor, accounting for over 50% of the trials, followed by the US with 29%, and the EU5 with 17%.

Breakdown of supply-side primary interviews, by company type, designation, and region:

• By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%)
• By Designation: C-level (35%), Director-level (45%), and Others (20%)
• By Region: North America (55%), Europe (20%), Asia Pacific (15%), Latin America (5%) and Middle East Africa (5%)

List of Companies Profiled in the Report

• IQVIA HOLDINGS INC. (North Carolina)
• Merative (Ann Arbor, MI)
• Optum Inc. (Eden Prairie)
• Icon Plc. (Dublin)
• Syneos Health (North Carolina),
• Parexel International Corporation (North Carolina)
• Thermo Fisher Scientific Inc. (North Carolina)
• LABORATORY CORPORATION OF AMERICA HOLDINGS (Burlington, North Carolina)
• Oracle (California)
• ELEVANCE HEALTH, INC. (Indiana)
• SAS Institute Inc. (North Carolina)
• Aetion Inc. (New York)
• Trinetx Llc. (Cambridge, MA)
• Trinity (Waltham)
• PerkinElmer, Inc. (Shelton, CT)
• COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION (New Jersey)
• Clinigen Group plc (London)
• Cegedim Health Data (Boulogne-Billancourt)
• Verantos (California)
• Medspace Holdings Inc. (Ohio)
• HealthVerity, Inc. (Philadelphia)
• Datavant (San Francisco, CA)
• Syapse, Inc. (San Francisco, CA)
• Tempus (Chicago, IL)
• Flatiron Health (New York)

Research Coverage

This report studies the Real-World Evidence Solution market based on components, application, end user, and region. The report also analyses factors (such as drivers, opportunities and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total Real-World Evidence Solution market. The report forecasts the revenue of the market segments with respect to five major regions.

Reasons to Buy the Report

This report also includes.

• Analysis of key drivers ( Increasing geriatric population and rise in incidences of chronic diseases, upsurging shift from volume to value-based care, and the increase in number of pharmaceutical and biopharmaceutical companies adapting the RWE), challenges (scarcity of skilled personnel, and the lack of universally accepted methodology principles and data processing infrastructure), opportunities (the rise in focus on end-to-end RWE services, and increase in emerging markets) contributing the growth of the Real-World Evidence Solution market.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the Real-World Evidence Solution market.
• Market Development: Comprehensive information on the lucrative emerging markets, components, application, end-user, and region.
• Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, investments in the Real-World Evidence Solution market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global real-world evidence solution Market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 OBJECTIVES OF THE STUDY
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS AND EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 REGIONS COVERED
  • FIGURE 1 REAL-WORLD EVIDENCE SOLUTIONS MARKET
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 LIMITATIONS
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES
• 1.7 RECESSION IMPACT

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • FIGURE 2 RESEARCH DESIGN
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
  • FIGURE 3 PRIMARY SOURCES
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key Industry Insights
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
• 2.2 RESEARCH METHODOLOGY DESIGN
  • FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
• 2.3 MARKET SIZE ESTIMATION
  • FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • 2.3.1 BOTTOM-UP APPROACH
  • FIGURE 7 REAL-WORLD EVIDENCE SOLUTIONS MARKET: BOTTOM-UP APPROACH
  • 2.3.2 TOP-DOWN APPROACH
  • FIGURE 8 REAL-WORLD EVIDENCE SOLUTIONS MARKET: TOP-DOWN APPROACH
  • FIGURE 9 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN REAL-WORLD EVIDENCE SOLUTIONS MARKET (2024-2029)
  • FIGURE 10 REAL-WORLD EVIDENCE SOLUTIONS MARKET: CAGR PROJECTIONS
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • FIGURE 11 DATA TRIANGULATION METHODOLOGY
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RISK ASSESSMENT
  • TABLE 1 RISK ASSESSMENT ANALYSIS
• 2.7 LIMITATIONS
  • 2.7.1 SCOPE-RELATED LIMITATIONS
  • 2.7.2 METHODOLOGY-RELATED LIMITATIONS
• 2.8 RECESSION IMPACT

3 EXECUTIVE SUMMARY

• FIGURE 12 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2024 VS. 2029 (USD MILLION)
• FIGURE 13 REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
• FIGURE 14 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2024 VS. 2029 (USD MILLION)
• FIGURE 15 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
• FIGURE 16 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2024 VS. 2029 (USD MILLION)
• FIGURE 17 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2024 VS. 2029 (USD MILLION)
• FIGURE 18 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2024 VS. 2029 (USD MILLION)
• FIGURE 19 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
• FIGURE 20 GEOGRAPHICAL SNAPSHOT OF REAL-WORLD EVIDENCE SOLUTIONS MARKET

4 PREMIUM INSIGHTS

• 4.1 REAL-WORLD EVIDENCE SOLUTIONS MARKET OVERVIEW
  • FIGURE 21 RISING GERIATRIC POPULATION AND SUBSEQUENT INCREASE IN PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
• 4.2 ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER AND COUNTRY (2023)
  • FIGURE 22 PHARMACEUTICAL & MEDICAL DEVICE COMPANIES ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023
• 4.3 REAL-WORLD EVIDENCE SOLUTIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • FIGURE 23 INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
• 4.4 REGIONAL MIX: REAL-WORLD EVIDENCE SOLUTIONS MARKET (2024-2029)
  • FIGURE 24 NORTH AMERICA WILL CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD
• 4.5 REAL-WORLD EVIDENCE SOLUTIONS MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES
  • FIGURE 25 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • FIGURE 26 REAL-WORLD EVIDENCE SOLUTIONS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • TABLE 2 MARKET DYNAMICS: IMPACT ANALYSIS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising geriatric population and subsequent increase in prevalence of chronic diseases
    • 5.2.1.2 Shift from volume-based care to value-based care
    • 5.2.1.3 Potential of RWE in reducing drug development costs and expediting drug development process
    • 5.2.1.4 Increased R&D spending for development of new pharmaceutical products and medical devices
  • FIGURE 27 NUMBER OF CLINICAL TRIALS, 2015-2020
    • 5.2.1.5 Support from regulatory bodies for use of RWE solutions
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Reluctance of medical practitioners and researchers to rely on real-world studies
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growth opportunities in emerging markets
    • 5.2.3.2 Increased focus on end-to-end RWE services
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Lack of universally accepted methodology standards and data processing infrastructure
    • 5.2.4.2 Shortage of skilled professionals
• 5.3 INDUSTRY TRENDS
  • 5.3.1 EMERGING ROLE OF WEARABLE DEVICES
  • 5.3.2 SOCIAL MEDIA-SOURCED RWE
  • 5.3.3 RISING USE OF RWD AND RWE ACROSS PHARMACEUTICAL INDUSTRY
  • FIGURE 28 RECOMMENDED INVESTMENT MODEL FOR RWD AND RWE
  • 5.3.4 INTERNAL VS. OUTSOURCED RWE ANALYTICS APPROACH
  • FIGURE 29 INTERNAL VS. OUTSOURCED RWE ANALYTICS APPROACH
  • 5.3.5 INCORPORATION OF ARTIFICIAL INTELLIGENCE IN RWD MANAGEMENT
• 5.4 REAL-WORLD DATA SOURCES
  • TABLE 3 INDICATIVE LIST OF NATIONAL DATABASES IN DEVELOPED COUNTRIES
• 5.5 ECOSYSTEM ANALYSIS
  • FIGURE 30 REAL-WORLD EVIDENCE SOLUTIONS MARKET: ECOSYSTEM
• 5.6 VALUE CHAIN ANALYSIS
  • FIGURE 31 REAL-WORLD EVIDENCE SOLUTIONS MARKET: VALUE CHAIN ANALYSIS
• 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
  • FIGURE 32 REVENUE SHIFT IN REAL-WORLD EVIDENCE SOLUTIONS MARKET
• 5.8 PORTER'S FIVE FORCES ANALYSIS
  • TABLE 4 PORTER'S FIVE FORCES ANALYSIS
  • 5.8.1 THREAT OF NEW ENTRANTS
  • 5.8.2 BARGAINING POWER OF SUPPLIERS
  • 5.8.3 BARGAINING POWER OF BUYERS
  • 5.8.4 THREAT OF SUBSTITUTES
  • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.9 PRICING ANALYSIS
  • 5.9.1 AVERAGE SELLING PRICE, BY KEY PLAYER
  • 5.9.2 INDICATIVE PRICE OF DATA SETS
• 5.10 TECHNOLOGY ANALYSIS
  • 5.10.1 KEY TECHNOLOGIES
    • 5.10.1.1 Use of AI and ML
    • 5.10.1.2 Blockchain technology
  • 5.10.2 ADJACENT TECHNOLOGIES
    • 5.10.2.1 Predictive analytics
    • 5.10.2.2 Visualization dashboard software
• 5.11 TARIFF AND REGULATORY LANDSCAPE
  • 5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 5 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.11.2 REGULATORY ANALYSIS
    • 5.11.2.1 North America
      • 5.11.2.1.1 US
        • 5.11.2.1.1.1 Case examples
      • 5.11.2.1.2 Canada
    • 5.11.2.2 Europe
    • 5.11.2.3 Asia Pacific
      • 5.11.2.3.1 China
      • 5.11.2.3.2 Japan
      • 5.11.2.3.3 India
• 5.12 PATENT ANALYSIS
  • 5.12.1 PATENT PUBLICATION TRENDS FOR RWE SOLUTIONS
  • FIGURE 33 PATENT PUBLICATION TRENDS IN REAL-WORLD SOLUTIONS MARKET, 2015-2023
  • 5.12.2 JURISDICTION AND TOP APPLICANT ANALYSIS
  • FIGURE 34 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTES) FOR REAL-WORLD EVIDENCE SOLUTION PATENTS (JANUARY 2015-DECEMBER 2023)
  • TABLE 6 LIST OF PATENTS IN REAL-WORLD EVIDENCE SOLUTIONS MARKET, 2019-2023
• 5.13 KEY CONFERENCES AND EVENTS
  • TABLE 7 REAL-WORLD EVIDENCE SOLUTIONS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
• 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 APPLICATIONS
  • TABLE 8 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 APPLICATIONS
  • 5.14.2 BUYING CRITERIA
  • FIGURE 36 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS
  • TABLE 9 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS
• 5.15 USE CASES/CASE STUDIES
  • 5.15.1 OPTIMIZING RWE WITH SCIENTIFICALLY RIGOROUS DATA-AGNOSTIC APPROACH
    • 5.15.1.1 Use case 1: Designing and building RWE dashboards and leveraging EHR and claims data
  • 5.15.2 UTILIZING DRUG DATA AND RWD TO ENHANCE PATIENT ADHERENCE
    • 5.15.2.1 Use case 2: Integrating specialty pharmacy and patient hub data with RWD data to investigate non-adherence factors
  • 5.15.3 EXISTING ANALYTICS TECHNOLOGY
    • 5.15.3.1 Use case 3: Simplifying data analytics with RWE platform
• 5.16 END-USER ANALYSIS
  • 5.16.1 UNMET NEEDS
  • TABLE 10 UNMET NEEDS IN REAL-WORLD EVIDENCE SOLUTIONS MARKET
  • 5.16.2 END-USER EXPECTATIONS
  • TABLE 11 END-USER EXPECTATIONS IN REAL-WORLD EVIDENCE SOLUTIONS MARKET
• 5.17 REAL-WORLD EVIDENCE SOLUTIONS BUSINESS MODEL
  • 5.17.1 PLATFORM AS A SERVICE (PAAS) MODEL
  • 5.17.2 DATA PROVIDER MODEL
  • 5.17.3 CONSULTING AND SERVICES MODEL
  • 5.17.4 COLLABORATIVE RESEARCH MODEL

6 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT

• 6.1 INTRODUCTION
  • TABLE 12 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
  • TABLE 13 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
• 6.2 SERVICES
  • 6.2.1 RISING NEED TO CONVERT DATA INTO ACTIONABLE EVIDENCE TO DRIVE DEMAND
  • TABLE 14 REAL-WORLD EVIDENCE SERVICES OFFERED BY KEY MARKET PLAYERS
  • TABLE 15 REAL-WORLD EVIDENCE SERVICES MARKET, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 16 REAL-WORLD EVIDENCE SERVICES MARKET, BY COUNTRY, 2023-2029 (USD MILLION)
• 6.3 DATA SETS
  • TABLE 17 REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 18 REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 19 REAL-WORLD EVIDENCE DATA SETS MARKET, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 20 REAL-WORLD EVIDENCE DATA SETS MARKET, BY COUNTRY, 2023-2029 (USD MILLION)
  • 6.3.1 DISPARATE DATA SETS
  • TABLE 21 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 22 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 23 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 24 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY COUNTRY, 2023-2029 (USD MILLION)
    • 6.3.1.1 Clinical settings data sets
      • 6.3.1.1.1 Increasing utilization of EHR data for trial recruitment to fuel growth
  • FIGURE 37 ADOPTION OF EHR, BY HOSPITAL SERVICE TYPE, 2019-2021
  • TABLE 25 CLINICAL SETTINGS DATA SETS OFFERED BY KEY MARKET PLAYERS
  • TABLE 26 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLINICAL SETTINGS DATA SETS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 27 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLINICAL SETTINGS DATA SETS, BY COUNTRY, 2023-2029 (USD MILLION)
    • 6.3.1.2 Claims data sets
      • 6.3.1.2.1 Growing need to understand economic benefits of drug reimbursement by payers to drive growth
  • TABLE 28 CLAIMS DATA SETS OFFERED BY KEY MARKET PLAYERS
  • TABLE 29 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLAIMS DATA SETS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 30 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLAIMS DATA SETS, BY COUNTRY, 2023-2029 (USD MILLION)
    • 6.3.1.3 Pharmacy data sets
      • 6.3.1.3.1 Increasing adoption of e-prescribing systems to drive growth
  • FIGURE 38 TOTAL E-PRESCRIPTIONS AND CONTROLLED SUBSTANCE PRESCRIPTIONS IN US (2018-2021)
  • TABLE 31 PHARMACY DATA SETS OFFERED BY KEY MARKET PLAYERS
  • TABLE 32 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PHARMACY DATA SETS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 33 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PHARMACY DATA SETS, BY COUNTRY, 2023-2029 (USD MILLION)
    • 6.3.1.4 Patient-powered data sets
      • 6.3.1.4.1 Increasing need to access opinions on diseases and treatments across social media to drive growth
  • TABLE 34 PATIENT-POWERED DATA SETS OFFERED BY KEY MARKET PLAYERS
  • TABLE 35 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PATIENT-POWERED DATA SETS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 36 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PATIENT-POWERED DATA SETS, BY COUNTRY, 2023-2029 (USD MILLION)
    • 6.3.1.5 Registry-based data sets
      • 6.3.1.5.1 Increasing number of disease registries to drive demand for registry-based data sets in evidence generation
  • TABLE 37 USE OF REGISTRIES FOR EVIDENCE GENERATION
  • TABLE 38 REGISTRY-BASED DATA SETS OFFERED BY KEY MARKET PLAYERS
  • TABLE 39 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR REGISTRY-BASED DATA SETS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 40 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR REGISTRY-BASED DATA SETS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 6.3.2 INTEGRATED DATA SETS
    • 6.3.2.1 Increasing demand for integrated data from multiple sources to drive growth
  • TABLE 41 INTEGRATED DATA SETS OFFERED BY KEY MARKET PLAYERS
  • TABLE 42 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR INTEGRATED DATA SETS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 43 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR INTEGRATED DATA SETS, BY COUNTRY, 2023-2029 (USD MILLION)

7 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION

• 7.1 INTRODUCTION
  • FIGURE 39 NUMBER OF CLINICAL TRIALS (COMPLETED), BY CONDITION/DISEASE, SEPTEMBER 2022
  • TABLE 44 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
  • TABLE 45 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
• 7.2 DRUG DEVELOPMENT & APPROVALS
  • TABLE 46 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
  • TABLE 47 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
  • TABLE 48 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 49 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 7.2.1 ONCOLOGY
    • 7.2.1.1 Growing number of clinical trials focused on cancer treatment to drive growth
  • TABLE 50 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR ONCOLOGY, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 51 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2029 (USD MILLION)
  • 7.2.2 CARDIOVASCULAR DISEASE
    • 7.2.2.1 High prevalence of CVD to support market growth
  • TABLE 52 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 53 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2023-2029 (USD MILLION)
  • 7.2.3 NEUROLOGY
    • 7.2.3.1 Rapidly aging global population and subsequent increase in prevalence of neurological disorders to drive growth
  • TABLE 54 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR NEUROLOGY, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 55 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR NEUROLOGY, BY COUNTRY, 2023-2029 (USD MILLION)
  • 7.2.4 IMMUNOLOGY
    • 7.2.4.1 Increasing focus on developing innovative products to drive growth
  • TABLE 56 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 57 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023-2029 (USD MILLION)
  • 7.2.5 OTHER THERAPEUTIC AREAS
  • TABLE 58 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 59 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2029 (USD MILLION)
• 7.3 MEDICAL DEVICE DEVELOPMENT & APPROVALS
  • 7.3.1 INCREASING RESEARCH IN MEDICAL DEVICE DEVELOPMENT TO DRIVE DEMAND
  • TABLE 60 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR MEDICAL DEVICE DEVELOPMENT & APPROVALS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 61 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR MEDICAL DEVICE DEVELOPMENT & APPROVALS, BY COUNTRY, 2023-2029 (USD MILLION)
• 7.4 POST-MARKET SURVEILLANCE
  • 7.4.1 EXTENSIVE USE OF RWE SOLUTIONS IN POST-MARKET SURVEILLANCE TO BOOST MARKET
  • TABLE 62 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR POST-MARKET SURVEILLANCE, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 63 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR POST-MARKET SURVEILLANCE, BY COUNTRY, 2023-2029 (USD MILLION)
• 7.5 MARKET ACCESS & REIMBURSEMENT/COVERAGE DECISION-MAKING
  • 7.5.1 GROWING USE OF RWE SOLUTIONS TO DEVELOP ECONOMIC AND BUDGET IMPACT MODELS TO FAVOR MARKET GROWTH
  • TABLE 64 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR MARKET ACCESS & REIMBURSEMENT/COVERAGE DECISION-MAKING, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 65 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR MARKET ACCESS & REIMBURSEMENT/COVERAGE DECISION-MAKING, BY COUNTRY, 2023-2029 (USD MILLION)
• 7.6 CLINICAL & REGULATORY DECISION-MAKING
  • 7.6.1 LIMITED VALIDITY OF RANDOMIZED CONTROLLED TRIALS TO DRIVE USE OF RWE SOLUTIONS
  • TABLE 66 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLINICAL & REGULATORY DECISION-MAKING, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 67 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLINICAL & REGULATORY DECISION-MAKING, BY COUNTRY, 2023-2029 (USD MILLION)

8 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL

• 8.1 INTRODUCTION
  • TABLE 68 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
  • TABLE 69 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
• 8.2 PAY PER USE (VALUE-BASED PRICING)
  • 8.2.1 RISING DEMAND FOR COST-EFFECTIVE AND FLEXIBLE SOLUTIONS TO BOOST MARKET
  • TABLE 70 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PAY-PER-USE (VALUE-BASED PRICING) MODELS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 71 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PAY-PER-USE (VALUE-BASED PRICING) MODELS, BY COUNTRY, 2023-2029 (USD MILLION)
• 8.3 SUBSCRIPTION
  • 8.3.1 RISING PREFERENCE FOR FLEXIBILITY AND SCALABILITY TO SUPPORT MARKET GROWTH
  • TABLE 72 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR SUBSCRIPTION MODELS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 73 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR SUBSCRIPTION MODELS, BY COUNTRY, 2023-2029 (USD MILLION)

9 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE

• 9.1 INTRODUCTION
  • TABLE 74 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
  • TABLE 75 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
• 9.2 ON-PREMISE
  • 9.2.1 ENHANCED DATA CONTROL BENEFITS TO BOOST DEMAND
  • TABLE 76 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR ON-PREMISE MODELS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 77 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR ON-PREMISE MODELS, BY COUNTRY, 2023-2029 (USD MILLION)
• 9.3 CLOUD-BASED
  • 9.3.1 INCREASED SCALABILITY AND FLEXIBILITY IN DATA COLLECTION TO DRIVE GROWTH
  • TABLE 78 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 79 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2023-2029 (USD MILLION)

10 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER

• 10.1 INTRODUCTION
  • TABLE 80 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
  • TABLE 81 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
• 10.2 PHARMACEUTICAL & MEDICAL DEVICE COMPANIES
  • 10.2.1 INCREASED R&D EXPENDITURE IN INNOVATIVE MEDICINES TO DRIVE MARKET GROWTH
  • TABLE 82 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 83 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023-2029 (USD MILLION)
• 10.3 HEALTHCARE PAYERS
  • 10.3.1 INCREASED FOCUS ON OUTCOME-BASED PAYMENT MODELS TO DRIVE DEMAND
  • TABLE 84 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PAYERS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 85 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PAYERS, BY COUNTRY, 2023-2029 (USD MILLION)
• 10.4 HEALTHCARE PROVIDERS
  • 10.4.1 GROWING FOCUS ON IMPROVING PROFITABILITY TO SUPPORT MARKET GROWTH
  • TABLE 86 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 87 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY, 2023-2029 (USD MILLION)
• 10.5 OTHER END USERS
  • TABLE 88 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER END USERS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 89 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2029 (USD MILLION)

11 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REGION

• 11.1 INTRODUCTION
  • TABLE 90 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REGION, 2018-2022 (USD MILLION)
  • TABLE 91 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REGION, 2023-2029 (USD MILLION)
• 11.2 NORTH AMERICA
  • 11.2.1 NORTH AMERICA: RECESSION IMPACT
  • FIGURE 40 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET SNAPSHOT
  • TABLE 92 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 93 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2023-2029 (USD MILLION)
  • TABLE 94 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
  • TABLE 95 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
  • TABLE 96 NORTH AMERICA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 97 NORTH AMERICA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 98 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 99 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 100 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
  • TABLE 101 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • TABLE 102 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
  • TABLE 103 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
  • TABLE 104 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
  • TABLE 105 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
  • TABLE 106 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
  • TABLE 107 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
  • TABLE 108 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
  • TABLE 109 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
  • 11.2.2 US
    • 11.2.2.1 US to hold largest share of North American market
  • TABLE 110 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
  • TABLE 111 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
  • TABLE 112 US: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 113 US: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 114 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 115 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 116 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
  • TABLE 117 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • TABLE 118 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
  • TABLE 119 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
  • TABLE 120 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
  • TABLE 121 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
  • TABLE 122 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
  • TABLE 123 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
  • TABLE 124 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
  • TABLE 125 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
  • 11.2.3 CANADA
    • 11.2.3.1 Rising number of clinical trials in Canada to drive market
  • TABLE 126 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
  • TABLE 127 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
  • TABLE 128 CANADA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 129 CANADA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 130 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 131 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 132 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
  • TABLE 133 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • TABLE 134 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
  • TABLE 135 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
  • TABLE 136 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
  • TABLE 137 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
  • TABLE 138 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
  • TABLE 139 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
  • TABLE 140 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
  • TABLE 141 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
• 11.3 EUROPE
  • 11.3.1 EUROPE: RECESSION IMPACT
  • TABLE 142 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 143 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2023-2029 (USD MILLION)
  • TABLE 144 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
  • TABLE 145 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
  • TABLE 146 EUROPE: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 147 EUROPE: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 148 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 149 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 150 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
  • TABLE 151 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • TABLE 152 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
  • TABLE 153 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
  • TABLE 154 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
  • TABLE 155 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
  • TABLE 156 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
  • TABLE 157 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
  • TABLE 158 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
  • TABLE 159 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
  • 11.3.2 GERMANY
    • 11.3.2.1 High pharmaceutical R&D spending in Germany to boost market growth
  • TABLE 160 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
  • TABLE 161 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
  • TABLE 162 GERMANY: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 163 GERMANY: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 164 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 165 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 166 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
  • TABLE 167 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • TABLE 168 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
  • TABLE 169 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
  • TABLE 170 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
  • TABLE 171 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
  • TABLE 172 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
  • TABLE 173 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
  • TABLE 174 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
  • TABLE 175 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
  • 11.3.3 UK
    • 11.3.3.1 Growing adoption of HTA to support market growth
  • TABLE 176 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
  • TABLE 177 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
  • TABLE 178 UK: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 179 UK: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 180 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 181 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 182 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
  • TABLE 183 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • TABLE 184 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
  • TABLE 185 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
  • TABLE 186 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
  • TABLE 187 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
  • TABLE 188 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
  • TABLE 189 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
  • TABLE 190 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
  • TABLE 191 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
  • 11.3.4 FRANCE
    • 11.3.4.1 High number of oncology clinical trials in France to drive market growth

• TABLE 192 FRANCE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
• TABLE 193 FRANCE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
• TABLE 194 FRANCE: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
• TABLE 195 FRANCE: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
• TABLE 196 FRANCE: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
• TABLE 197 FRANCE: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
• TABLE 198 FRANCE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
• TABLE 199 FRANCE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
• TABLE 200 FRANCE: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
• TABLE 201 FRANCE: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
• TABLE 202 FRANCE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
• TABLE 203 FRANCE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
• TABLE 204 FRANCE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
• TABLE 205 FRANCE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
• TABLE 206 FRANCE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
• TABLE 207 FRANCE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
• 11.3.5 ITALY
  • 11.3.5.1 High demand for RWE due to widespread use of pay-for-outcomes to drive market
• TABLE 208 ITALY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
• TABLE 209 ITALY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
• TABLE 210 ITALY: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
• TABLE 211 ITALY: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
• TABLE 212 ITALY: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
• TABLE 213 ITALY: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
• TABLE 214 ITALY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
• TABLE 215 ITALY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
• TABLE 216 ITALY: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
• TABLE 217 ITALY: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
• TABLE 218 ITALY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
• TABLE 219 ITALY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
• TABLE 220 ITALY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
• TABLE 221 ITALY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
• TABLE 222 ITALY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
• TABLE 223 ITALY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
• 11.3.6 SPAIN
  • 11.3.6.1 Rising R&D expenditure to propel market growth in Spain
• TABLE 224 SPAIN: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
• TABLE 225 SPAIN: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
• TABLE 226 SPAIN: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
• TABLE 227 SPAIN: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
• TABLE 228 SPAIN: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
• TABLE 229 SPAIN: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
• TABLE 230 SPAIN: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
• TABLE 231 SPAIN: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
• TABLE 232 SPAIN: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
• TABLE 233 SPAIN: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
• TABLE 234 SPAIN: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
• TABLE 235 SPAIN: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
• TABLE 236 SPAIN: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
• TABLE 237 SPAIN: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
• TABLE 238 SPAIN: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
• TABLE 239 SPAIN: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
• 11.3.7 REST OF EUROPE
• TABLE 240 REST OF EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
• TABLE 241 REST OF EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
• TABLE 242 REST OF EUROPE: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
• TABLE 243 REST OF EUROPE: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
• TABLE 244 REST OF EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
• TABLE 245 REST OF EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
• TABLE 246 REST OF EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
• TABLE 247 REST OF EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
• TABLE 248 REST OF EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
• TABLE 249 REST OF EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
• TABLE 250 REST OF EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
• TABLE 251 REST OF EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
• TABLE 252 REST OF EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
• TABLE 253 REST OF EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
• TABLE 254 REST OF EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
• TABLE 255 REST OF EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
• 11.4 ASIA PACIFIC
  • 11.4.1 ASIA PACIFIC: RECESSION IMPACT
  • FIGURE 41 ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET SNAPSHOT
  • TABLE 256 ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 257 ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2023-2029 (USD MILLION)
  • TABLE 258 ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
  • TABLE 259 ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
  • TABLE 260 ASIA PACIFIC: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 261 ASIA PACIFIC: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 262 ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 263 ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 264 ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
  • TABLE 265 ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • TABLE 266 ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
  • TABLE 267 ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
  • TABLE 268 ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
  • TABLE 269 ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
  • TABLE 270 ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
  • TABLE 271 ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
  • TABLE 272 ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
  • TABLE 273 ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
  • 11.4.2 JAPAN
    • 11.4.2.1 Stringent regulatory scenario in Japan to restrain market growth
  • TABLE 274 JAPAN: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
  • TABLE 275 JAPAN: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
  • TABLE 276 JAPAN: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 277 JAPAN: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 278 JAPAN: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 279 JAPAN: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 280 JAPAN: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
  • TABLE 281 JAPAN: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • TABLE 282 JAPAN: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
  • TABLE 283 JAPAN: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
  • TABLE 284 JAPAN: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
  • TABLE 285 JAPAN: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
  • TABLE 286 JAPAN: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
  • TABLE 287 JAPAN: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
  • TABLE 288 JAPAN: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
  • TABLE 289 JAPAN: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
  • 11.4.3 CHINA
    • 11.4.3.1 Low cost of clinical trials and large pharmaceutical R&D base in China to drive market
  • TABLE 290 CHINA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
  • TABLE 291 CHINA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
  • TABLE 292 CHINA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 293 CHINA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 294 CHINA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 295 CHINA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 296 CHINA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
  • TABLE 297 CHINA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • TABLE 298 CHINA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
  • TABLE 299 CHINA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
  • TABLE 300 CHINA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
  • TABLE 301 CHINA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
  • TABLE 302 CHINA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
  • TABLE 303 CHINA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
  • TABLE 304 CHINA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
  • TABLE 305 CHINA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
  • 11.4.4 INDIA
    • 11.4.4.1 Growing adoption of outcome-based research to drive market
  • TABLE 306 INDIA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
  • TABLE 307 INDIA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
  • TABLE 308 INDIA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 309 INDIA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 310 INDIA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 311 INDIA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 312 INDIA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
  • TABLE 313 INDIA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • TABLE 314 INDIA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
  • TABLE 315 INDIA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
  • TABLE 316 INDIA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
  • TABLE 317 INDIA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
  • TABLE 318 INDIA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
  • TABLE 319 INDIA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
  • TABLE 320 INDIA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
  • TABLE 321 INDIA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
  • 11.4.5 REST OF ASIA PACIFIC
  • TABLE 322 REST OF ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
  • TABLE 323 REST OF ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
  • TABLE 324 REST OF ASIA PACIFIC: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 325 REST OF ASIA PACIFIC: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 326 REST OF ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 327 REST OF ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 328 REST OF ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
  • TABLE 329 REST OF ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • TABLE 330 REST OF ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
  • TABLE 331 REST OF ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
  • TABLE 332 REST OF ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
  • TABLE 333 REST OF ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
  • TABLE 334 REST OF ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
  • TABLE 335 REST OF ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
  • TABLE 336 REST OF ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
  • TABLE 337 REST OF ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
• 11.5 LATIN AMERICA
  • 11.5.1 LATIN AMERICA: RECESSION IMPACT
  • TABLE 338 LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 339 LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2023-2029 (USD MILLION)
  • TABLE 340 LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
  • TABLE 341 LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
  • TABLE 342 LATIN AMERICA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 343 LATIN AMERICA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 344 LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 345 LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 346 LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
  • TABLE 347 LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • TABLE 348 LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
  • TABLE 349 LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
  • TABLE 350 LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
  • TABLE 351 LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
  • TABLE 352 LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
  • TABLE 353 LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
  • TABLE 354 LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
  • TABLE 355 LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
  • 11.5.2 BRAZIL
    • 11.5.2.1 Brazil to hold largest share of LATAM market
  • TABLE 356 BRAZIL: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
  • TABLE 357 BRAZIL: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
  • TABLE 358 BRAZIL: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 359 BRAZIL: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 360 BRAZIL: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 361 BRAZIL: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 362 BRAZIL: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
  • TABLE 363 BRAZIL: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • TABLE 364 BRAZIL: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
  • TABLE 365 BRAZIL: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
  • TABLE 366 BRAZIL: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
  • TABLE 367 BRAZIL: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
  • TABLE 368 BRAZIL: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
  • TABLE 369 BRAZIL: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
  • TABLE 370 BRAZIL: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
  • TABLE 371 BRAZIL: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
  • 11.5.3 MEXICO
    • 11.5.3.1 Rising funding and investment in pharma R&D to favor growth
  • TABLE 372 MEXICO: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
  • TABLE 373 MEXICO: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
  • TABLE 374 MEXICO: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 375 MEXICO: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 376 MEXICO: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 377 MEXICO: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 378 MEXICO: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
  • TABLE 379 MEXICO: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • TABLE 380 MEXICO: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
  • TABLE 381 MEXICO: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
  • TABLE 382 MEXICO: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
  • TABLE 383 MEXICO: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
  • TABLE 384 MEXICO: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
  • TABLE 385 MEXICO: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
  • TABLE 386 MEXICO: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
  • TABLE 387 MEXICO: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
  • 11.5.4 REST OF LATIN AMERICA
  • TABLE 388 REST OF LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
  • TABLE 389 REST OF LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
  • TABLE 390 REST OF LATIN AMERICA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 391 REST OF LATIN AMERICA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 392 REST OF LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 393 REST OF LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 394 REST OF LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
  • TABLE 395 REST OF LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • TABLE 396 REST OF LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
  • TABLE 397 REST OF LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
  • TABLE 398 REST OF LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
  • TABLE 399 REST OF LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
  • TABLE 400 REST OF LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
  • TABLE 401 REST OF LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
  • TABLE 402 REST OF LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
  • TABLE 403 REST OF LATIN AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
  • TABLE 404 MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REGION, 2018-2022 (USD MILLION)
  • TABLE 405 MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REGION, 2023-2029 (USD MILLION)
  • TABLE 406 MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
  • TABLE 407 MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
  • TABLE 408 MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 409 MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 410 MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 411 MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 412 MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
  • TABLE 413 MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • TABLE 414 MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
  • TABLE 415 MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
  • TABLE 416 MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
  • TABLE 417 MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
  • TABLE 418 MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
  • TABLE 419 MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
  • TABLE 420 MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
  • TABLE 421 MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Growing availability of healthcare funding to offer opportunities for market growth
  • TABLE 422 GCC COUNTRIES: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
  • TABLE 423 GCC COUNTRIES: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
  • TABLE 424 GCC COUNTRIES: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 425 GCC COUNTRIES: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 426 GCC COUNTRIES: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 427 GCC COUNTRIES: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 428 GCC COUNTRIES: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
  • TABLE 429 GCC COUNTRIES: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • TABLE 430 GCC COUNTRIES: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
  • TABLE 431 GCC COUNTRIES: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
  • TABLE 432 GCC COUNTRIES: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
  • TABLE 433 GCC COUNTRIES: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
  • TABLE 434 GCC COUNTRIES: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
  • TABLE 435 GCC COUNTRIES: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
  • TABLE 436 GCC COUNTRIES: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
  • TABLE 437 GCC COUNTRIES: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
  • 11.6.3 REST OF MIDDLE EAST & AFRICA
  • TABLE 438 REST OF MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
  • TABLE 439 REST OF MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
  • TABLE 440 REST OF MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 441 REST OF MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 442 REST OF MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018-2022 (USD MILLION)
  • TABLE 443 REST OF MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023-2029 (USD MILLION)
  • TABLE 444 REST OF MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
  • TABLE 445 REST OF MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • TABLE 446 REST OF MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
  • TABLE 447 REST OF MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
  • TABLE 448 REST OF MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018-2022 (USD MILLION)
  • TABLE 449 REST OF MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023-2029 (USD MILLION)
  • TABLE 450 REST OF MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018-2022 (USD MILLION)
  • TABLE 451 REST OF MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023-2029 (USD MILLION)
  • TABLE 452 REST OF MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
  • TABLE 453 REST OF MIDDLE EAST & AFRICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
  • TABLE 454 REAL-WORLD EVIDENCE SOLUTIONS MARKET: STRATEGIES ADOPTED
• 12.3 REVENUE SHARE ANALYSIS
  • FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS (2018-2022)
• 12.4 MARKET SHARE ANALYSIS
  • FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
  • TABLE 455 REAL-WORLD EVIDENCE SOLUTIONS MARKET: DEGREE OF COMPETITION
• 12.5 MARKET RANKING ANALYSIS
  • FIGURE 44 REAL-WORLD EVIDENCE SOLUTIONS MARKET RANKING, BY KEY PLAYER, 2023
• 12.6 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 45 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY KEY PLAYER
  • 12.6.1 IQVIA HOLDINGS INC. (US)
  • 12.6.2 MERATIVE (US)
  • 12.6.3 ICON PLC (IRELAND)
  • 12.6.4 FLATIRON HEALTH (US)
  • 12.6.5 VERANTOS (US)
  • 12.6.6 TRINETX, LLC (US)
• 12.7 VALUATION AND FINANCIAL METRICS OF REAL-WORLD EVIDENCE SOLUTIONS VENDORS
  • FIGURE 46 EV/EBITDA OF KEY VENDORS
• 12.8 COMPANY EVALUATION MATRIX: KEY PLAYERS
  • 12.8.1 STARS
  • 12.8.2 EMERGING LEADERS
  • 12.8.3 PERVASIVE PLAYERS
  • 12.8.4 PARTICIPANTS
  • FIGURE 47 REAL-WORLD EVIDENCE SOLUTIONS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • 12.8.5 COMPANY FOOTPRINT
  • FIGURE 48 REAL-WORLD EVIDENCE SOLUTIONS MARKET: COMPANY FOOTPRINT
  • TABLE 456 REAL-WORLD EVIDENCE SOLUTIONS MARKET: COMPONENT FOOTPRINT
  • TABLE 457 REAL-WORLD EVIDENCE SOLUTIONS MARKET: END-USER FOOTPRINT
  • TABLE 458 REAL-WORLD EVIDENCE SOLUTIONS MARKET: REGIONAL FOOTPRINT
• 12.9 COMPANY EVALUATION MATRIX: START-UPS/SMES
  • 12.9.1 PROGRESSIVE COMPANIES
  • 12.9.2 RESPONSIVE COMPANIES
  • 12.9.3 DYNAMIC COMPANIES
  • 12.9.4 STARTING BLOCKS
  • FIGURE 49 REAL-WORLD EVIDENCE SOLUTIONS MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
  • 12.9.5 COMPETITIVE BENCHMARKING
  • TABLE 459 REAL-WORLD EVIDENCE SOLUTIONS MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • TABLE 460 REAL-WORLD EVIDENCE SOLUTIONS MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES
• 12.10 COMPETITIVE SCENARIO
  • 12.10.1 PRODUCT LAUNCHES/ENHANCEMENTS
  • TABLE 461 REAL-WORLD EVIDENCE SOLUTIONS MARKET: PRODUCT LAUNCHES/ENHANCEMENTS, JANUARY 2020-DECEMBER 2023
  • 12.10.2 DEALS
  • TABLE 462 REAL-WORLD EVIDENCE SOLUTIONS MARKET: DEALS, JANUARY 2020-DECEMBER 2023

13 COMPANY PROFILES

(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)**

• 13.1 KEY PLAYERS
  • 13.1.1 IQVIA HOLDINGS INC.
  • TABLE 463 IQVIA HOLDINGS INC.: COMPANY OVERVIEW
  • FIGURE 50 IQVIA HOLDINGS INC.: COMPANY SNAPSHOT (2022)
  • TABLE 464 IQVIA HOLDINGS INC: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2020-DECEMBER 2023
  • TABLE 465 IQVIA HOLDINGS INC.: DEALS, JANUARY 2020-DECEMBER 2023
  • 13.1.2 MERATIVE
  • TABLE 466 MERATIVE: COMPANY OVERVIEW
    • 13.1.2.2 Products/Services/Solutions offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Deals
  • TABLE 467 MERATIVE: DEALS, JANUARY 2020-DECEMBER 2023
  • 13.1.3 OPTUM, INC.
  • TABLE 468 OPTUM, INC.: COMPANY OVERVIEW
  • FIGURE 51 OPTUM, INC.: COMPANY SNAPSHOT (2022)
  • TABLE 469 OPTUM, INC.: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2020-DECEMBER 2023
  • 13.1.4 ICON PLC
  • TABLE 470 ICON PLC: COMPANY OVERVIEW
  • FIGURE 52 ICON PLC: COMPANY SNAPSHOT (2022)
  • TABLE 471 ICON PLC: DEALS, JANUARY 2020-DECEMBER 2023
  • 13.1.5 SYNEOS HEALTH, INC.
  • TABLE 472 SYNEOS HEALTH INC.: COMPANY OVERVIEW
  • FIGURE 53 SYNEOS HEALTH INC.: COMPANY SNAPSHOT (2022)
  • TABLE 473 SYNEOS HEALTH, INC.: DEALS, JANUARY 2020-DECEMBER 2023
  • 13.1.6 PAREXEL INTERNATIONAL CORPORATION
  • TABLE 474 PAREXEL INTERNATIONAL CORPORATION: COMPANY OVERVIEW
  • TABLE 475 PAREXEL INTERNATIONAL CORPORATION: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2020-DECEMBER 2023
  • TABLE 476 PAREXEL INTERNATIONAL CORPORATION: DEALS, JANUARY 2020-DECEMBER 2023
  • 13.1.7 THERMO FISHER SCIENTIFIC INC.
  • TABLE 477 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • FIGURE 54 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
    • 13.1.7.2 Products/Services/Solutions offered
    • 13.1.7.3 Recent developments
  • TABLE 478 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2020-DECEMBER 2023
  • 13.1.8 FORTREA INC.
  • TABLE 479 FORTREA INC.: COMPANY OVERVIEW
  • 13.1.9 ORACLE CORPORATION
  • TABLE 480 ORACLE CORPORATION: COMPANY OVERVIEW
  • FIGURE 55 ORACLE CORPORATION: COMPANY SNAPSHOT (2022)
  • TABLE 481 ORACLE CORPORATION: DEALS, JANUARY 2020-DECEMBER 2023
  • 13.1.10 ELEVANCE HEALTH, INC.
  • TABLE 482 ELEVANCE HEALTH, INC.: COMPANY OVERVIEW
  • FIGURE 56 ELEVANCE HEALTH, INC.: COMPANY SNAPSHOT (2022)
  • TABLE 483 ELEVANCE HEALTH, INC.: DEALS, JANUARY 2020-DECEMBER 2023
  • 13.1.11 SAS INSTITUTE INC.
  • TABLE 484 SAS INSTITUTE INC.: COMPANY OVERVIEW
  • TABLE 485 SAS INSTITUTE INC.: DEALS, JANUARY 2020-DECEMBER 2023
  • 13.1.12 AETION, INC.
  • TABLE 486 AETION, INC.: COMPANY OVERVIEW
  • TABLE 487 AETION, INC.: DEALS, JANUARY 2020-DECEMBER 2023
  • 13.1.13 TRINETX LLC
  • TABLE 488 TRINETX LLC: COMPANY OVERVIEW
  • TABLE 489 TRINETX LLC: PRODUCT LAUNCHES, JANUARY 2020-DECEMBER 2023
  • TABLE 490 TRINETX LLC: DEALS, JANUARY 2020-DECEMBER 2023
  • 13.1.14 TRINITY
  • TABLE 491 TRINITY: COMPANY OVERVIEW
  • TABLE 492 TRINITY: DEALS, JANUARY 2020-DECEMBER 2023
  • 13.1.15 PERKINELMER INC.
  • TABLE 493 PERKINELMER INC.: COMPANY OVERVIEW
  • FIGURE 57 PERKINELMER INC.: COMPANY SNAPSHOT (2022)
  • TABLE 494 PERKINELMER INC.: PRODUCT LAUNCHES, JANUARY 2020-DECEMBER 2023
  • 13.1.16 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION
  • TABLE 495 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: COMPANY OVERVIEW
  • FIGURE 58 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: COMPANY SNAPSHOT (2022)
  • 13.1.17 CEGEDIM HEALTH DATA
  • TABLE 496 CEGEDIM HEALTH DATA: COMPANY OVERVIEW
  • TABLE 497 CEGEDIM HEALTH DATA: DEALS, JANUARY 2020-DECEMBER 2023
  • 13.1.18 VERANTOS
  • TABLE 498 VERANTOS: COMPANY OVERVIEW
  • TABLE 499 VERANTOS INC.: DEALS, JANUARY 2020-DECEMBER 2023
  • 13.1.19 MEDPACE HOLDINGS, INC.
  • TABLE 500 MEDPACE HOLDINGS, INC.: COMPANY OVERVIEW
  • FIGURE 59 MEDPACE HOLDINGS, INC.: COMPANY SNAPSHOT (2022)
• 13.2 OTHER PLAYERS
  • 13.2.1 HEALTHVERITY, INC.
  • TABLE 501 HEALTHVERITY, INC.: COMPANY OVERVIEW
  • 13.2.2 DATAVANT
  • TABLE 502 DATAVANT: COMPANY OVERVIEW
  • 13.2.3 SYAPSE, INC.
  • TABLE 503 SYAPSE, INC.: COMPANY OVERVIEW
  • 13.2.4 TEMPUS
  • TABLE 504 TEMPUS: COMPANY OVERVIEW
  • 13.2.5 FLATIRON HEALTH
  • TABLE 505 FLATIRON HEALTH: COMPANY OVERVIEW
  • 13.2.6 QUANTZIG
  • TABLE 506 QUANTZIG: COMPANY OVERVIEW
• *Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)** might not be captured in case of unlisted companies.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS

관련자료